<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="HAEB0B58060EF4C929C20EF3C04C61AE8" key="H" public-private="public"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 5176 IH: Preventing Overdoses While in Emergency Rooms Act of 2018</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2018-03-06</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">115th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 5176</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20180306">March 6, 2018</action-date><action-desc><sponsor name-id="M001180">Mr. McKinley</sponsor> (for himself and <cosponsor name-id="D000482">Mr. Michael F. Doyle of Pennsylvania</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To require the Secretary of Health and Human Services to provide coordinated care to patients who
			 have experienced a non-fatal overdose after emergency room discharge, and
			 for other purposes.</official-title></form>
	<legis-body id="HDDACD53FEB3E4112AF823F829A97C7E0" style="OLC">
 <section id="H5B61350326164AB3ADA86C22F9EF47A2" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Preventing Overdoses While in Emergency Rooms Act of 2018</short-title></quote>.</text> </section><section id="HB59BECDB0B244CD09D25E03FAD96C834"><enum>2.</enum><header>Program to support emergency room discharge and care coordination for drug overdose patients</header> <subsection id="H666D13E41F8F4FB1A16D70346E929CC6"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">The Secretary of Health and Human Services shall establish a program (in this Act referred to as the <quote>Program</quote>) to develop protocols for discharging patients who have presented with a drug overdose and enhance the integration and coordination of care and treatment options for individuals with substance use disorder after discharge.</text>
			</subsection><subsection id="HD30FFC3081084B928A17C3EC53D81517"><enum>(b)</enum><header>Grant establishment and participation</header>
 <paragraph id="H5CF1E3DF8D1A444B9DA406A893FE6344"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">In carrying out the Program, the Secretary shall award grants on a competitive basis to not more than 20 eligible health care sites described in paragraph (2).</text>
 </paragraph><paragraph id="H551D279DDBE9442EB4FCF2B293E07604"><enum>(2)</enum><header>Eligible health care sites</header><text display-inline="yes-display-inline">To be eligible for a grant under this section, a health care site shall—</text> <subparagraph commented="no" id="H80ED8E5DA4FC4AEAA09AD375A46AF432"><enum>(A)</enum><text>submit an application to the Secretary at such time, in such manner, and containing such information as specified by the Secretary;</text>
 </subparagraph><subparagraph id="HAB4A5532066E4B5EB2E0D9520B1895D1"><enum>(B)</enum><text>have an emergency department;</text> </subparagraph><subparagraph id="H5020C635CC7240BFBA382D54E553AF49"><enum>(C)</enum> <clause commented="no" display-inline="yes-display-inline" id="H0110F2F5CFCE4C5985031183278B927F"><enum>(i)</enum><text display-inline="yes-display-inline">have a licensed health care professional on site who has a waiver under section 303(g) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)</external-xref>) to administer medication-assisted treatment; or</text>
 </clause><clause id="H7182A51B5EAB4A05AA9B41C86047369B" indent="up1"><enum>(ii)</enum><text>have a demonstrable plan to hire a full-time licensed health care professional who has a waiver described in clause (i) to administer such treatment on site;</text>
 </clause></subparagraph><subparagraph id="H2DB2203E256F4762843C805939F22543"><enum>(D)</enum><text display-inline="yes-display-inline">have in place an agreement with a sufficient number and range of entities certified under applicable State and Federal law, such as pursuant to registration or a waiver under section 303(g) of the Controlled Substances Act (<external-xref legal-doc="usc" parsable-cite="usc/21/823">21 U.S.C. 823(g)</external-xref>) or certification as described in section 8.2 of title 42 of the Code of Federal Regulations, to provide treatment for substance use disorder such that, in combination, the resulting network of entities with an agreement with the hospital cumulatively are capable of providing services for all evidence-based services for the treatment of substance use disorder, as medically appropriate for the individual involved, including—</text>
 <clause id="H6714618D3C28401986B6ED108EC96AC3"><enum>(i)</enum><text display-inline="yes-display-inline">medication-assisted treatment;</text> </clause><clause id="HB2BCA88606864C119F16E9A992771649"><enum>(ii)</enum><text display-inline="yes-display-inline">withdrawal and detoxification services that include patient evaluation, stabilization, and readiness for and entry into treatment; and</text>
 </clause><clause id="H28B8A325A3074D5CAB34DBA4FC417BFA"><enum>(iii)</enum><text>counseling;</text> </clause></subparagraph><subparagraph id="H8FC9E6ED30F94B28A937B81662053004"><enum>(E)</enum><text display-inline="yes-display-inline">deploy on-site peer recovery specialists to help connect patients with treatment and recovery support programs; and</text>
 </subparagraph><subparagraph id="H01F4801F0FF144739C8A188F456F85E8"><enum>(F)</enum><text>include the provision of overdose reversal medication in discharge protocols for opioid overdose patients.</text>
 </subparagraph></paragraph><paragraph id="H2767A4AAF451414A86AFC4DFED75B4F4"><enum>(3)</enum><header>Preference</header><text>In awarding grants under this section, the Secretary shall give preference to eligible health care sites that meet either or both of the following criteria:</text>
 <subparagraph id="HCB9E1C0B2F03444DBFCC7159B541B8D1"><enum>(A)</enum><text>The site is a critical access hospital (as defined in section 1861(mm)(1) of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395x">42 U.S.C. 1395x(mm)(1)</external-xref>)), a low-volume hospital (as defined in section 1886(d)(12)(C)(i) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(d)(12)(C)(i)</external-xref>)), or a sole community hospital (as defined in section 1886(d)(5)(D)(iii) of such Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395ww">42 U.S.C. 1395ww(d)(5)(D)(iii)</external-xref>)).</text>
 </subparagraph><subparagraph id="H2982B79C87894BD6A3DFD0C3F40F7CA7"><enum>(B)</enum><text display-inline="yes-display-inline">The site is located in a geographic area with an overdose rate higher than the national average, based on the most recent data of the Centers for Disease Control and Prevention.</text>
 </subparagraph></paragraph><paragraph id="HDE17AEF20BD34C358D97189E2400E993"><enum>(4)</enum><header>Medication-assisted treatment defined</header><text display-inline="yes-display-inline">For purposes of this section, the term <term>medication-assisted treatment</term> means the use of medication approved by the Food and Drug Administration in combination with behavioral health services to provide an individualized approach to the treatment of substance use disorders, including opioid use disorder.</text>
 </paragraph></subsection><subsection id="H480C3492FF2D4934A993635959A8E423"><enum>(c)</enum><header>Period of grant</header><text display-inline="yes-display-inline">A grant awarded to an eligible health care site under this section shall be for a period of at least 2 years.</text>
			</subsection><subsection commented="no" id="HF4BCF1A8F7AD43CA946E358E9FC9BA34"><enum>(d)</enum><header>Grant uses</header>
 <paragraph commented="no" id="HE22D5E2ACDED4B1193251EE567AD471E"><enum>(1)</enum><header>Required uses</header><text display-inline="yes-display-inline">A grant awarded under this section to an eligible health care site shall be used for both of the following purposes:</text>
 <subparagraph commented="no" id="H79EFE6AB20A649EE9D4A48ADB081AC60"><enum>(A)</enum><text display-inline="yes-display-inline">To establish policies and procedures that address the provision of overdose reversal medication, the administration of medication-assisted treatment to a non-fatal overdose patient in the emergency department, and the subsequent referral to evidence-based treatment upon discharge for patients who have experienced a non-fatal drug overdose.</text>
 </subparagraph><subparagraph commented="no" id="H6143ABF7A42448B285E77FA4D79FE65A"><enum>(B)</enum><text display-inline="yes-display-inline">To develop best practices for treating non-fatal drug overdoses, including with respect to care coordination and integrated care models for long term treatment and recovery options for individuals who have experienced a non-fatal drug overdose.</text>
 </subparagraph></paragraph><paragraph commented="no" id="HE0E3498D429A45C687474CAAE62F5279"><enum>(2)</enum><header>Additional permissible uses</header><text display-inline="yes-display-inline">A grant awarded under this section to an eligible health care site may be used for any of the following purposes:</text>
 <subparagraph commented="no" id="H07B26F14365346EDA43DFD36D48BC0FE"><enum>(A)</enum><text display-inline="yes-display-inline">To hire emergency department peer recovery specialists; counselors; therapists; social workers; or other licensed medical professionals specializing in the treatment of substance use disorder.</text>
 </subparagraph><subparagraph commented="no" id="HCE1414A530504771A9F15F5C12FA19FB"><enum>(B)</enum><text display-inline="yes-display-inline">To establish integrated models of care for individuals who have experienced a non-fatal drug overdose which may include patient assessment, follow up, and transportation to treatment facilities.</text>
 </subparagraph><subparagraph commented="no" id="H077A500760AF44D0AA51CA39BE5BB405"><enum>(C)</enum><text>To provide for options for increasing the availability and access of medication-assisted treatment and other evidence-based treatment for individuals with substance use disorders.</text>
					</subparagraph></paragraph></subsection><subsection id="HF3CC2AF96BAA470AB5E8961AD20742DA"><enum>(e)</enum><header>Reporting requirements</header>
 <paragraph id="H5DAFA1EEA9D146A0A4DCCA1F79D7BBAB"><enum>(1)</enum><header>Reports by grantees</header><text display-inline="yes-display-inline">Each eligible health care site awarded a grant under this section shall submit to the Secretary an annual report for each year for which the site has received such grant that includes information on—</text>
 <subparagraph id="H7F4779385020442A8FFF07575EE3BAD3"><enum>(A)</enum><text display-inline="yes-display-inline">the number of individuals treated at the site for non-fatal overdoses in the emergency department;</text> </subparagraph><subparagraph id="H4A1358A394ED41128FE42BA6615E27D5"><enum>(B)</enum><text>the number of individuals administered medication-assisted treatment at the site in the emergency department;</text>
 </subparagraph><subparagraph id="H5900D297AB2F4ADBAE43D2A1DCDB7A10"><enum>(C)</enum><text>the number of individuals referred by the site to other treatment facilities after a non-fatal overdose, the types of such other facilities, and the number of such individuals admitted to such other facilities pursuant to such referrals;</text>
 </subparagraph><subparagraph id="HF75FF45F226A498D87D763C2BC144441"><enum>(D)</enum><text display-inline="yes-display-inline">the frequency and number of patient readmissions for non-fatal overdoses and substance abuse disorder;</text>
 </subparagraph><subparagraph id="H0D50EFC14610423CA22DE4675B941FA5"><enum>(E)</enum><text>for what the grant funding was used; and</text> </subparagraph><subparagraph id="HC2BC59CF91FF4B68B255AEB367273533"><enum>(F)</enum><text>the effectiveness of, and any other relevant additional data regarding, having an onsite health care professional to administer and begin medication-assisted treatment for substance use disorders.</text>
 </subparagraph></paragraph><paragraph commented="no" id="H1E39BB538401496CAAFABB327912355D"><enum>(2)</enum><header>Report by Secretary</header><text display-inline="yes-display-inline">Not less than one year after the conclusion of the Program, the Secretary shall submit to Congress a report that includes—</text>
 <subparagraph commented="no" id="H010945FF7BF74D64BFA3E89C177D428C"><enum>(A)</enum><text>findings of the Program;</text> </subparagraph><subparagraph commented="no" id="H799ACB52169441C9966D4B754C6188D4"><enum>(B)</enum><text>overall patient outcomes under the Program, such as with respect to hospital readmission;</text>
 </subparagraph><subparagraph commented="no" id="H94E89709A1C4404A8261D3B6B5FDD966"><enum>(C)</enum><text>what percentage of patients treated by a site receiving a grant under this section were readmitted to a hospital for non-fatal or fatal overdose; and</text>
 </subparagraph><subparagraph commented="no" id="HFF423B65F7D148B9A4DE8489F916D136"><enum>(D)</enum><text>a compilation of voluntary guidelines and best practices from the reports submitted under paragraph (1).</text>
 </subparagraph></paragraph></subsection><subsection id="H50BA59124A78499F98F0A2FB7A40796C"><enum>(f)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">There is authorized to be appropriated to carry out this Act $50,000,000 for the period of fiscal years 2019 through 2023.</text>
			</subsection></section></legis-body></bill>


